EP4621803A1 — Method for identifying patients in need for ici-induced myotoxicity treatment
Assigned to Assistance Publique Hopitaux de Paris APHP · Expires 2025-09-24 · 1y expired
What this patent protects
The invention pertains to the field of cancer treatment by Immune Checkpoint Inhibitors (ICls) and to the risk stratification and personalized treatment of patients having ICI-induced myotoxicity.
USPTO Abstract
The invention pertains to the field of cancer treatment by Immune Checkpoint Inhibitors (ICls) and to the risk stratification and personalized treatment of patients having ICI-induced myotoxicity.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.